// App-Quantinova.ai

e14100 : Effect of itraconazole or rifampicin on the pharmacokinetics (PK) of osimertinib (AZD9291).

Researchers

Presenter

  • Karthick Vishwanathan

Principal Investigators

  • James Chih-Hsin Yang

  • Jong-Seok Lee

  • Matthew Krebs

  • Paul A. Dickinson

  • Khanh Bui

  • Doris Weilert

  • Karen So

  • Karen Thomas

  • R Donald Harvey

Medical Centers

  • Quantitative Clinical Pharmacology, AstraZeneca, Waltham, MA

  • Experimental Cancer Medicine Team, The Christie NHS Foundation Trust, Manchester, United Kingdom

  • Seda Pharmaceutical Development Services, Alderley Edge, United Kingdom

  • Quintiles Inc., Overland Park, Leawood, KS

  • Biostatics and Informatics, AstraZeneca, Macclesfield, United Kingdom

  • Winship Cancer Institute of Emory University, Atlanta, GA

Locations

  • United States

  • Taiwan

  • United Kingdom

Companies

  • Quintiles and IMS He

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Itraconazole

  • Canadiol

  • Tagrisso

  • rifampicin

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • I

Study Id's

  • NCT02157883

  • NCT02197247

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved